Overview

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

Status:
Completed
Trial end date:
2019-04-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the pharmacokinetics (PK) profile of a single dose of AMG 592 administered subcutaneously in healthy Japanese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen